logo-loader
RNS
viewAvacta Group PLC

Issue of Equity

/**/ sup{font-size:80%}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .ai{size:595.0pt 842.0pt;margin:63.8pt 72.0pt 2.0cm 72.0pt;}div.ai{}p.cd{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; margin-bottom: 0cm; text-align: center}span.cb{font-size:11.0pt;font-family: "Calibri","sans-serif"}p.ce{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; margin-bottom: 0cm}span.bz{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.cf{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-bottom:0cm;margin-bottom:.0001pt}p.cg{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-bottom: 0cm; text-align: right}p.ch{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-bottom: 0cm; text-align: center}p.ci{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;text-justify:inter-ideograph;line-height:115%} span.cj{font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"}span.bt{font-size:11.0pt; line-height:115%;font-family:"Calibri","sans-serif"}span.bs{font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"; color:black;background:white}span.bq{font-size: 11.0pt;line-height:115%;font-family:"Calibri","sans-serif";color:black}span.bp{font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"; color:black}p.ck{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;text-justify:inter-ideograph}p.cl{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 115%; text-align: justify; text-justify: inter-ideograph}span.bn{font-size:10.0pt;line-height:115%; font-family:"Arial","sans-serif";color:black}table.cm{width:460.4pt;margin-left:-5.1pt;border-collapse:collapse}tr.be{height:43.9pt} td.bh{width:245.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:43.9pt}p.cn{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; margin-bottom: 3.0pt; text-align: justify; text-justify: inter-ideograph}span.bl{font-size:10.0pt;font-family: "Arial","sans-serif";color:black}p.co{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-bottom:3.0pt;text-align:justify;text-justify: inter-ideograph}span.bj{font-size:10.0pt;font-family:"Arial","sans-serif"; color:black}td.bf{width:193.8pt;padding:0cm 5.4pt 0cm 5.4pt; height:43.9pt}span.bg{font-size:10.0pt;font-family:"Arial","sans-serif";color:black}tr.az{height:99.2pt}td.bd{width:245.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:99.2pt}td.ba{width:193.8pt;padding:0cm 5.4pt 0cm 5.4pt; height:99.2pt} p.cp{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-bottom: 3.0pt; text-align: justify; text-decoration: underline; text-justify: inter-ideograph}span.cq{font-family:"Times New Roman","serif";color:blue;text-decoration:underline;color: black; font-family: "Arial","sans-serif"; font-size: 10.0pt; text-decoration: none}td.aw{width:245.0pt;padding:0cm 5.4pt 0cm 5.4pt}span.ay{font-size:10.0pt;font-family: "Arial","sans-serif"}span.ax{font-size:10.0pt;font-family:"Arial","sans-serif"}td.at{width:193.8pt;padding:0cm 5.4pt 0cm 5.4pt}span.av{font-size: 10.0pt;font-family:"Arial","sans-serif"}span.au{font-family: "Arial","sans-serif"; font-size: 10.0pt; text-decoration: underline}p.cr{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 115%; margin: 0cm; margin-bottom: .0001pt; text-align: justify; text-justify: inter-ideograph}span.ar{font-size:10.0pt; line-height:115%;font-family:"Arial","sans-serif";color:black} p.cs{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify; text-justify:inter-ideograph;line-height:115%}span.ap{font-size:10.0pt;line-height:115%;font-family: "Arial","sans-serif";color:black}p.ct{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify; text-justify:inter-ideograph;line-height:115%}span.cu{font-family:"Times New Roman","serif";font-size:10.0pt;line-height:115%;font-family:"Arial","sans-serif"; color:black}span.am{font-size:10.0pt;line-height: 115%;font-family:"Arial","sans-serif";color:black}p.cv{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";text-align:justify;text-justify:inter-ideograph; line-height:115%}span.al{font-size:10.0pt;line-height:115%;font-family:"Arial","sans-serif"}span.an{font-size:10.0pt;line-height:115%;font-family:"Arial","sans-serif"; color:black}span.aj{font-size:10.0pt;line-height:115%; font-family:"Arial","sans-serif"} /**/
RNS Number : 8446W
Avacta Group PLC
23 April 2019
 

 

 

 

 

 

23 April 2019

 

Avacta Group plc

 

("Avacta" or "the Group" or "the Company")

 

Issue of Equity

 

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, today announces that following the exercise of share options by a founder shareholder in an historic acquisition it has issued and allotted 201,652 new ordinary shares of 10 pence each in the Company ("Ordinary Shares").

 

Application has been made for the Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 30 April 2019. The Ordinary Shares will rank pari passu with the existing Ordinary Shares of the Company.

 

Following Admission, the Company's enlarged issued share capital will be 116,158,123. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

-Ends -

 

 

For further information from Avacta Group plc, please contact:

 

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

 

Tel:  +44 (0) 844 414 0452

https://www.avacta.com/

finnCap Ltd

Geoff Nash / Giles Rolls - Nominated Adviser

Tim Redfern - ECM

 

WG Partners

Nigel Birks / Nigel Barnes

David Wilson / Claes Spang

 

Tel:  +44 (0) 207 220 0500

www.finncap.com

 

 

Tel:  +44 (0) 203 705 9318

Tel:  +44 (0) 203 705 9217

www.wgpartners.co.uk

 

Turner Pope Investments

James Pope

Ben Turner

 

Zyme Communications (Trade and Regional Media)

Katie Odgaard

 

Yellow Jersey (Financial Media and IR)

Sarah Hollins

Harriet Jackson

Tel: 020 3621 4120

www.turnerpope.com

 

 

Tel: +44 (0)7787 502 947

[email protected] 

 

 

Tel: +44 (0)7764 947137

Tel: +44 (0)7544 275882

[email protected]

 

 

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

 

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer® technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability.  Affimer® technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer® reagents through licensing to developers of life sciences research tools and diagnostics.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
IOEUOOSRKSASUAR

Quick facts: Avacta Group PLC

Price: 20.25

Market: AIM
Market Cap: £35.63 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Avacta Plc's therapeutics business 'has huge amount of potential' - analyst...

Capital Network analyst Ed Stacey discusses the major value driver for Avacta - the development of its proprietary Affimer technology for therapeutics, particularly in the immune-oncology (I-O) space. The group's reported interim results to January 2019 today, revealing revenues of...

on 9/4/19

RNS

Holding(s) in Company

1 week, 1 day ago

Holding(s) in Company

1 week, 3 days ago

Holding(s) in Company

1 week, 3 days ago

Holding(s) in Company

1 week, 4 days ago

Holding(s) in Company

1 week, 5 days ago

Holding(s) in Company

1 week, 5 days ago